EUVIMEDEUVIMED entdecken
Open Access

Multifunctional Engineered Metal–Organic Frameworks as Targeted Protein Degraders for Augmenting Cancer Therapy via Hexokinase 2 Degradation and Provoking Cuproptosis

Shasha Li, Runjie Liu, Qixuan Zhang, Jiahui Sun, Hao Hao, Chenhao Yao, Li Yan, Dan Yang, Dechun Liu iD

Research · 01.01.2026 · 9

DOI: 10.34133/research.1217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research, online erschienen am 31.03.2026. Verfasst von Shasha Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research & Development Institute of Northwestern Polytechnical University in Shenzhen, Guangdong 518057, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi Province, Shenzhen Science and Technology Innovation Program.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cuproptosis, a newly identified form of copper-dependent programmed cell death, has emerged as a potential therapeutic strategy for cancer treatment. However, its antitumor efficacy was strictly limited by dysregulated glycolytic metabolism of tumor cells. Herein, we proposed multifunctional copper-based nano-PROTACs (CHNDs) to degrade hexokinase 2 (HK-2) and amplify cuproptosis for cancer therapy via dual mitochondrial energy depletion. Our initial evaluation indicated that polyethyleneimine (PEI)-based nano-PROTACs (PHDs) triggered HK-2 degradation via the ubiquitin–proteasome system (UPS). PHDs reduced HK-2 expression to 43.7% in 4T1 cells and 42.1% in CT26 cells, which consequently impaired glycolysis in tumor cells. Furthermore, copper ion release from CHNDs in a controlled manner and the glucose metabolism homeostasis interference by PHDs orchestrally induced effective cuproptosis and glycolysis inhibition for suppressing development and metastasis of tumor cells. Notably, CHNDs markedly inhibited the growth of murine colon and breast tumors by simultaneously disrupting mitochondrial respiration and glycolysis, resulting in tumor inhibition rates of 76.6% and 55.3%, respectively, and extending the median survival of CT26 tumor-bearing mice from 21 to 29 d. Our designed multifunctional engineered nanoparticle-based targeted protein degraders facilitated a new paradigm for precise oncology and proteolysis-targeting chimera (PROTAC) development.

Autor:innen und Institutionen

  • Research & Development Institute of Northwestern Polytechnical University in Shenzhen, Guangdong 518057, China.
  • School of Life Science and Technology, Northwestern Polytechnical University, Xi'an, Shaanxi 710072, China.
  • Department of Pharmaceutical Sciences, School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology, Weiyang University Park, Xi'an 710021, China.

ORCID-Profile: Dechun Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Basic Research Program of Shaanxi Province
  • Shenzhen Science and Technology Innovation Program
  • the Innovation Capability Support Program of Shaanxi
  • Shaanxi Province Postdoctoral Science Foundation

Zitieren

APA

Li, S., Liu, R., Zhang, Q., Sun, J., Hao, H., Yao, C., Yan, L., Yang, D., & Liu, D. (2026). Multifunctional Engineered Metal–Organic Frameworks as Targeted Protein Degraders for Augmenting Cancer Therapy via Hexokinase 2 Degradation and Provoking Cuproptosis. Research, 9. https://doi.org/10.34133/research.1217

Vancouver

Li S, Liu R, Zhang Q, Sun J, Hao H, Yao C, et al. Multifunctional Engineered Metal–Organic Frameworks as Targeted Protein Degraders for Augmenting Cancer Therapy via Hexokinase 2 Degradation and Provoking Cuproptosis. Research. 2026;9. doi:10.34133/research.1217

BibTeX
@article{Li2026,
  author = {Li, Shasha and Liu, Runjie and Zhang, Qixuan and Sun, Jiahui and Hao, Hao and Yao, Chenhao and Yan, Li and Yang, Dan and Liu, Dechun},
  title = {Multifunctional Engineered Metal–Organic Frameworks as Targeted Protein Degraders for Augmenting Cancer Therapy via Hexokinase 2 Degradation and Provoking Cuproptosis},
  journal = {Research},
  year = {2026},
  volume = {9},
  doi = {10.34133/research.1217}
}
Kostenlos starten →